| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6cda19c11d98cc99f3034a45ecd2691a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_312631533d53ba52fa172956084a07da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08751582dcacff6c6377cf1ff6b66fe6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a7361f51434afc7c7548bbc91c179fd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2011-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbd38cf3a8d4bca930d8c20dd8dfc625
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_889db920f903c8d0008ec004a59d0bc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_208105c6cb203070f067bc41664280c5 |
| publicationDate |
2012-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012082209-A1 |
| titleOfInvention |
Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| abstract |
The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above. |
| priorityDate |
2010-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |